Drug Trial Radar · NCT04621136
PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity
Last checked: Nov 19, 2026Latest source record: Feb 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Nov 1, 2020
Primary completion
Nov 30, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Kyushu UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 4 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm phase I/II trial to evaluate the safety and efficacy of Rho-associated protein kinase(ROCK) inhibitor Ripasudil eye drops for preterm infants with Retinopathy of Prematurity(ROP).
Conditions
- Retinopathy of Prematurity
Interventions
Ripasudil ophthalmic solution 0.4%Drug
Phase1 A total of three infants will receive ripasudil eye drops(0.4%) once daily for one week, followed by twice-daily drug administration for two weeks. The three infants who participate in Phase1 can continue to receive the eye drop treatment for additional 9 weeks(12 weeks in total)if the investigators determine that there are no safety issues with ripasudil. In addition, a data and safety monitoring board(DSMB)will be held two times to decide whether the new patients can be enrolled into phase1, and also if phase2 can begin. Phase2:A total of 21 patients will receive ripasudil eye drops(0.4%)twice daily for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with Adverse Events(AEs) and Adverse Drug Reactions(ADRs)Time frame: throughout the study duration(up to week16)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Kyushu University Hospital
Fukuoka, Japan
University Hospital of Occupational and Environmental Health
Kitakyushu, Fukuoka, Japan
Yamaguchi University Hospital
Ube, Yamaguchi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.